Hepatic Metabolic Disorders
Akero Therapeutics Inc. concentrates its research efforts on addressing complex liver conditions associated with metabolic dysfunction. The organisation investigates therapeutic interventions targeting non-alcoholic steatohepatitis (NASH), a progressive form of fatty liver disease characterised by hepatic inflammation and cellular damage. Their clinical programmes examine the pathophysiology of metabolic dysfunction-associated steatohepatitis (MASH), focusing on the interplay between hepatic lipid accumulation, inflammatory processes, and fibrotic tissue development.
- Non-Alcoholic Steatohepatitis and Liver Fibrosis
- Metabolic Dysfunction-Associated Steatohepatitis
- Hepatic Lipotoxicity and Inflammation
The sponsor’s research portfolio emphasises the development of novel pharmacological approaches to halt or reverse liver fibrosis progression in patients with metabolically driven hepatic disease. Their investigations explore mechanisms that address both the metabolic and inflammatory components underlying chronic liver injury.
Fibrotic Liver Disease
The organisation pursues advanced therapeutic strategies targeting hepatic fibrogenesis and the structural remodelling of liver tissue. Research activities focus on understanding the cellular and molecular mechanisms that drive extracellular matrix deposition in the liver, with particular attention to the transition from reversible fibrosis to irreversible cirrhosis. The sponsor investigates interventions designed to modulate stellate cell activation and collagen synthesis pathways.
- Liver Fibrosis Regression and Stabilisation
- Cirrhotic Disease Management
- Hepatic Stellate Cell Biology
Clinical investigations examine biomarkers of fibrosis progression and therapeutic endpoints related to histological improvement in liver architecture. The research emphasises identifying patients at risk for advanced fibrotic disease and developing treatments that can meaningfully alter the natural history of chronic liver conditions.
Cardiometabolic Complications
Akero Therapeutics Inc. explores the systemic metabolic disturbances that frequently accompany chronic liver disease. The sponsor’s research addresses dyslipidaemia, insulin resistance, and glucose metabolism disorders that contribute to both hepatic and cardiovascular pathology. Clinical programmes investigate the bidirectional relationship between liver disease and metabolic syndrome, examining how hepatic dysfunction influences systemic metabolic homeostasis.
- Lipid Metabolism and Dyslipidaemia
- Insulin Sensitivity and Glucose Regulation
- Cardiovascular Risk in Metabolic Liver Disease
The organisation’s investigations encompass the metabolic complications that increase morbidity and mortality in patients with fatty liver disease, including atherosclerotic cardiovascular disease risk factors. Research efforts focus on therapeutic approaches that address multiple components of the cardiometabolic disease spectrum simultaneously.
